Advances in Cancer Therapies 2004

=======================================================
Advances in Cancer Therapies 2004
Oncology Research, Novel Biologics and Pharmacogenomics
=======================================================
15th and 16th September 2004, Workshop 14th September 2004
Hilton Kensington Hotel, London


  **FINAL AGENDA BELOW**
**REQUEST YOUR BROCHURE TODAY**

Visiongain b2b Conferences is pleased to announce that 'Advances in Cancer Therapies 2004 - Oncology Research, Novel Biologics and Pharmacogenomics' will be run in mid September this year. This event will follow up on the success of 'Cancer Drugs 2003'. The agenda is nearing completion, now is your chance to register your interest in speaking, sponsoring or attending this leading event.

THEMES TO BE INCLUDED:

**Identify Key market Segments and Profit From Emerging Trends in Cancer Therapeutics
**Clinical Trials for Cancer- How can Your Company Bring a Drug to Trial and  Advice on Overcome Delays
**Learn From the Best Practice Case Studies such as: Zometa-  MabThera- Erbitux- ABX-EGF- Oncophage
**Examine Areas Shaping the Future of Cancer Therapies:
  -Monoclonal Antibodies 
  -Antisense Drugs 
  -Vaccines  
  -Angiogenesis Inhibitors
**Pharmacogenomics- Assess the Advances in Personalisation of Cancer Therapies
**Discover how Alliances will Shape the Future of Cancer Therapy, Highlighting Opportunities

KEY SPEAKERS

**Dr. Bruno Osterwalder, VP, Global Head, Early & Strategic Oncology, Roche
**Dr. Peter Blume-Jensen, Head & Director, Molecular Oncology, Serono
**Dr. Jean-Francois Pouliot, Director of Scientific Research- Onclogy, Schering Plough
**Yong Jiang Hei, Senior Medical Brand Director- Zometa, Novartis
**Uday Bose, Taxotere Marketing, Aventis Oncology 
**Dr. Iris Kuss, COE Study Management Europe, Schering
**Francisco Sapunar, Clinical Research Physician, AstraZeneca
**Dr. Dimitris Voliotis, Director, Global Clinical Leader, Oncology, Bayer HealthCare
**Dr. Peter Bohlen, Senior VP, Research, ImClone Systems
**Dr. Raymond Withy, President & CEO, Abgenix
**Dr. Nick Dean, Vice President Functional Genomics, Isis Pharmaceuticals
**Dr. Renu Gupta, Senior Vice President, Development, Antigenics

WHO SHOULD ATTEND THIS EVENT:

**Vice President, Clinical Oncology
**Director of Oncology Development
**Vice President of Clinical Research
**Program Director, Cancer
**Senior Director, Clinical Research
**Director, Experimental Medicine
**Medical Director
**Executive Director for Development
**Global Head of Oncology

----------------------------------------------------------------- 
This event will also feature: Pre-conference Interactive Workshop
----------------------------------------------------------------- 

**Strategies for Pricing and Market Access of New Oncology Drugs**
  Tuesday 14th September 2004
  Led by: Ulf Munack, Director, Simon-Kucher & Partners

This workshop will give you the opportunity to engage in
knowledge-sharing with fellow professionals, which can result in
brainstorming and creating ideas which you can use back in your
own organisation. 

You can gain a greater understanding of the
pathology of pain, have detailed discussions about pain signalling
pathways and ventures for new targets.


---------------------
DELEGATE REGISTRATION
---------------------

Places at this event are limited, please call or email me now to secure your place

- PRICING -
Attend the:
** Conf. + pre conf. workshop GBP 1600.00 Plus VAT 
** Conference only Fee: GBP 1299.00 Plus VAT
** Pre conference workshop only Fee: GBP 650.00 Plus VAT 

- BOOKINGS -
Booking is easy, simply contact Harry Grant on:
Telephone: +44 (0)20 8767 6711
Fax: +44 (0)20 8767 5001
Email: mailto:[email protected]
Terms and conditions apply - see below.

If you have any further questions regarding this event and how you can be involved please do not hesitate to ask.

Kind regards,

Harry Grant
Account Manager
Visiongain B2B Conferences
Telephone: +44 (0)20 8767 6711
Fax: +44 (0)20 8767 5001
Email: mailto:[email protected]


++++++
AGENDA
++++++

PRE-CONFERENCE INTERACTIVE WORKSHOP
Strategies for Pricing and Market Access of New Oncology Drugs
Tuesday 14th September 2004
Led by: Ulf Munack, Director, Simon-Kucher & Partners

It is of most use to those who are willing and prepared to engage
in meaningful discussions and network with others. This
'facilitated open-space' provides you with ideas and time to
explore possible new targets of action and benchmark them
against other approaches.

Main topics of discussion:
* P&R environment for cancer products in 2004
* Critical success factors for market access in
oncology
* Examples of recent learning from new oncology
launches

Schedule: The workshop will run from 10:00 until 14:00 with lunch and refreshments at appropriate intervals

-------------------------------------
Day One Wednesday 15th September 2004
-------------------------------------

09:00 Registration and coffee

09:30 Opening remarks from the Chair

CLINICAL TRIALS IN CANCER

09:40 New Approaches to Clinical Development: Assess What
Will Suit your Needs
* Maximum tolerated dose and biological effective dose:advice
  on maximising their use
* How to get accurate dose:response information
* How significant is shrinkage/ no shrinkage to your clinical
  development? -assess and implement
* Reliability of tumour markers- how far should you depend on
  them? -practical advice
* Assessment of combination therapy of new drugs with
  traditional ones - will it work for your drugs?

Dr. MariaGrazia Porro
Associate Director- Clinical Research/Oncology
Nerviano Medical Science

10:20 Signal Transduction-Based Drug Discovery: Oncogenic
Kinase Signalling and Molecularly Targeted Therapeutics
* Major post-translational regulatory mechanisms
  -Reversible protein and lipid phosphorylation controlling cell
  function
* Causal involvement in human malignancies and immune
  disorders- perturbation of the normal regulatory mechanisms
  controlling kinase and phosphatase activity
* Examples from Serono's kinase drug discovery program
* What are the major future challenges for kinase inhibitors as
  therapeutics? -how to overcome them

Dr. Peter Blume-Jensen
Head & Director, Molecular Oncology
Serono

11:00 Morning Coffee

11:20 Design, Interpretation and Outcomes of Phase IIa/IIb
Trials in Oncology - The Clinical Perspective
* How to cope with the transition from phase I to II
* Objectives, endpoints, design and patient population
* What's different with targeted/ cytostatic vs cytotoxic
  compounds?
* Analysis of results and transition into phase III

Dr. Dimitris Voliotis
Director, Global Clinical Leader, Oncology
Bayer HealthCare

COMMERCIAL DEVELOPMENT: CASE STUDIES

12:00 CASE STUDY: Arimidex, A Novel Adjuvant Treatment for
Early Breast Cancer in Postmenopausal Women
* Current market for aromatase inhibitors
* First and only AI to be approved in EBC: impact of efficacy and
  safety analysis in market capture
* Post marketing results: Belgium, Mexico and Japan
* New Results: increased DFS in early adjuvant and switching
  strategies. What is the real impact in recurrence?

Francisco Sapunar
Clinical Research Physician
AstraZeneca

12:40 Lunch

14:00 CASE STUDY: Zometa, the First Drug to be approved for
Treating Bone Metastases from all solid tumors
* Causes of bone metastases: liquid tumours, solid tumours,
  side-effect and how to overcome them
* Zometa: a powerful version of Aredia? an update
* Safety and efficacy considerations- what Aventis has learnt
* Zometa for more tumour types- lungs, breast, prostate,
  multiple myeloma and renal
* Potential in market sector - pointers for share capture

Yong Jiang Hei
Senior Medical Brand Director, Zometa
Novartis

14:40 CASE STUDY: Taxotere, How it has Become the World's
Largest Selling Breast Cancer Treatment
* Competitors in the field and how to keep the edge
* Market capture in other indications
  - non small cell lung cancer, gastric, ovarian and neck cancer
* FDA approved new indication- prostate cancer: the future for
  Taxotere?
* Methods used to establish Taxotere with clinicians- how to
  optimise market penetration

Uday Bose
Taxotere Marketing
Aventis Oncology

15:20 Afternoon Tea

15:40 The Dawn of a New Era in Cancer Therapy
* What did we learn from the evolution of cancer therapy with
  some practical examples
* The emergence of targeted therapies: what determines their
  success?
* Where are we going and what will be the impact of the
  human genome project?

Dr. Jean-Francois Pouliot
Director of Scientific Research
Schering-Plough

MONOCLONAL ANTIBODY THERAPIES

16:20 CASE STUDY: ABX-EGF, the Monoclonal Antibody
Generated by XenoMouse Technology
* Phase II clinical results: kidney, non-small cell lung, colorectal
  and prostate cancers
* XenoMouse technology- how can you use it to generate
  antibodies
* Key product characteristics: using differences between ABX-EGF
  and drugs targeting the EGF receptor and pathway

Dr. Raymond Withy
President & CEO
Abgenix

16:40 Questions and Discussion

17:00 Summation of day one from conference chair

17:10 Close of Day One

------------------------------------
Day Two Thursday 16th September 2004
------------------------------------

09:00 Registration and Coffee

09:30 Opening remarks from the Chair

09:40 CASE STUDY: MabThera, the Primary Drug for Treatment
of Non-Hodgkin Lymphoma
* Therapeutic work of MabThera- binding to CD20 antigen
* Breakdown of success in event-free survival in patients with
  aggressive non-Hodgkin lymphona
* New indications: Rituxan for non-malignant autoimmune
  disorders?
* Results of ongoing trials- where have we succeeded and how
* Up and coming competitors to MabThera and strategies to
  maintain market lead

Dr. Bruno Osterwalder
VP, Global Head, Early & Strategic Oncology
Roche

10:20 CASE STUDY: Zevalin, A Novel Treatment Regime
Zevalin is the first product with a monoclonal antibody that is
combined with a radioactive chemical for the treatment of non-Hodgkin
lymphoma
* Two part administration of Zevalin: screening and treatment
* Results from safety and efficacy studies
* Toxicity of treatment- limiting use and how to overcome this
* How effective is it in patients who are refractory to antibody
  treatment?

Dr. Iris Kuss
COE Study Management Europe
Schering

11:00 Morning Coffee

NOVEL BIOLOGICS: ANTISENSE

11:20 How can You Get Antisense onto the Market
* Developing novel and specific classes of drugs- how to rapidly
  and effectively capitalize on information
* Recent advances in oligonucleotide technology- how will this
  impact the process of your drug discovery?
* Developing antisense oligonucleotides as therapeutic agents
* Antisense mechanisms- RNase H based and siRNA
* Status and progress of antisense in clinical studies in oncology

Dr. Nick Dean
VP, Functional Genomics
Isis Pharmaceuticals

NOVEL BIOLOGICS: VACCINES

12:00 CASE STUDY: Oncophage, the Invesigational Personalised
Melanoma Vaccine
* Capturing the antigenic footprint- how to use this to control
  cancer
* Advantages over conventional treatment- no more debilitating
  side effects
* Fast track status- what will this mean to the market
* Ongoing product development strategies: clinical trials to
  efficacy data

Dr. Renu Gupta
Senior VP, Development
Antigenics

12:40 Lunch

NOVEL BIOLOGICS: ANGIOGENESIS INHIBITORS
14:00 CASE STUDY: Commercialisation of Thalidomide
* Proposed mechanism of Thalidomide action
* S.T.E.P.S: a unique distribution system
* The role of the independent investigator in clinical trials
* Thalidomide as a treatment for haematological and
  oncological conditions- is it effective?
* Clinical development of the ImiDs and SelCIDs

Dr. Ken Watters
VP, Clinical Develpment and Regulatory Affairs
Celgene Europe Limited

14:40 Anti-Angiogenic Strategies: Targeting the VEGF
Receptors KDR and flt1
* Proteins and small molecules as anti-angiogenic agents
* Ongoing preclinical research- how to get it right
* KDR antibody phase I studies and efficacy in a leukemia model
* Therapeutic potential of VEGFR1 (flt1)
* VEGF receptor antibodies in a model of atherosclerosis
* Current research goals: increasing efficacy and tolerability

Dr. Peter Bohlen
Senior VP, Research
ImClone Systems

15:20 Afternoon Tea

PHARMACEUTICAL ALLIANCES

15:40 CASE STUDY: HAP Technology for Pharmaceutical
Research
* DNA-based diagnostics and therapeutic products
  - Integrating genetic variation and population genomics
  - developing, marketing and prescribing
* HAP database and DecoGen Informatics System
* STRENGTH study: AstraZeneca licensing agreement

Krishnan Nandabalan
VP, Business Development
Genaissance

16:20 Big Pharma and Biotech Alliances: Perlegen Sciences
Case Study
* Perlegen-identified single nucleotides: DNA scanning
  technology
* Genome scanning project
* Benefits of scanning clinical trial participants
* Multiple collaborations

Paul Cusenza
VP, Alliance Management
Perlegen Sciences

17:00 Questions and Discussion

17:20 Chairman summation

17:30 Close of Conference











Terms & Conditions
NB - Due to high demand, we do not 'reserve' or 'hold' places - a request for an invoice to be raised will be treated as an official booking and will be subject to the cancellation policy as outlined below.
Cancellations/substitutions and name changes: All bookings carry a 50% liability after the booking has been made, by post fax, email or web. There will be no refunds for cancellations received on or after one month before the start of the conference (e.g. cancellation on or after 20th January for a conference starting on 20th February). If you decide to cancel after this date the full invoice remains payable. Conference notes, which are available on the day, will be sent to you. Unfortunately we are not able to transfer places between conferences and executive briefings. However if you are unable to attend the event you may make a substitution/name change at any time as long as we are informed in writing by e-mail, fax or post. Name changes and substitutions must be from the same company and are not transferable between companies or countries.

Indemnity: visiongain Ltd reserve the right to change the conference/executive briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled due to acts of terrorism, war, extreme weather conditions, industrial action, acts of God or any event beyond the control of visiongain Ltd. If such a situation arises we will endeavour to reschedule the event. However, visiongain Ltd cannot be held responsible for any cost, damage or expenses, which may be incurred by the customer as a consequence of the event being postponed or cancelled. We therefore strongly advise all customers to take out insurance to cover the cost of the registration, travel and expenses.

To unsubscribe please reply with unsubscribe in the subject line. 

Data protection: Visiongain Ltd gathers and manages data in accordance with the Data Protection Act 1998. Information contained about you may be used to update you on visiongain Ltd products and services via post, telephone, fax or email, unless you state otherwise. If you wish your details to be amended, please send your request to the Database Manager, visiongain Ltd, 40 Tooting High Street, London, SW17 0RG. Alternatively please reply with unsubscribe in the subject line. Please allow approximately 7 days for your removal or update request, you may receive additional pieces of communication from visiongain Ltd during the transitional period, whilst the changes come into effect.







#####################################################################################

This email has been scanned by MailMarshal, an email content filter. 

#####################################################################################
#####################################################################################

This email has been scanned by MailMarshal, an email content filter. 

#####################################################################################
#####################################################################################

This email has been scanned by MailMarshal, an email content filter. 

#####################################################################################